Nicholas Short MD

Associate Professor, Department of Leukemia, MD Anderson Cancer Center - Research interest: phase I/II clinical trials in AML and ALL, developing new MRD assays

[Leticia Campoverde @LetyCampoverde]

Grateful to receive an ASCO Young Investigator Award for our work investigating mechanisms of resistance and response to momelotinib plus gilteritinib in FLT3-mutated AML.
Thank you to my mentors @HusseinAbbasLab and @NicholasShortMD for their guidance and support #ASCO2026

[Walid Macaron, MD MSc @WNMacaron]

Our new review explores how the definition of high-risk Ph+ ALL is shifting across tx eras.
Risk is dynamic, shaped by the interplay of biology, response, and treatment context. We examine key determinants, their evolving relevance, and risk-adapted strategies in the current era.

[Jessica Altman, MD @jaltmanmd]

Kudos @Daver_Leukemia and @NicholasShortMD on not just your beautiful work but your outstanding mentorship of Dr. Azevedo! Outstanding long term follow up for aza ven gilt for adults w FLT3m AML inappropriate IC. #ASH25 #ASHScavengerHunt

[Walid Macaron, MD MSc @WNMacaron]

Check out our most recent publication in @BloodCancerJnl evaluating the prognostic impact of early NGS-based MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL.

https://t.co/uR43j02ClQ

@NicholasShortMD @DrHKantarjian
#Leusm #ALLsm

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

🚨 long-term outcomes in FLT3-m AML w/frontline HMA+VEN+FLT3 i
🔴93% CR/CRi in ND FLT3-m AML.
🔴3-yr OS: 45% (FLT3-ITD), 76% (FLT3-TKD)
🔴RASp mutations ➡️ poor survival
🔴ITD NGS MRD highly prognostic
🔴FLT3 wild-type relapses common. #Leusm #hemepath
https://t.co/zBTFAL24fQ

[Hagop Kantarjian,MD @DrHKantarjian]

WBC >70K (but not IKZF1plus) increases risk of relapse with blina+ponatinib in Ph+ ALL, particularly extramedullary/CNS. Pts with high WBC should be considered for systemic MTX/Ara-C and/or CAR T-cell consolidation
https://t.co/yqiIPUPxhG
#leusm #ALL

[Blood Advances @BloodAdvances]

Measurable residual disease is a powerful predictor of clinical outcomes in acute lymphoblastic leukemia. https://t.co/BF3bMC9ZLS #MRD #ALL #lymphoidneoplasia

[Hagop Kantarjian,MD @DrHKantarjian]

Expert recommendations on using MRD in #ALL now out in @BloodAdvances. ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT
@MDAndersonNews #Leukemia
https://t.co/eQLDCAbR4H
#leusm

[ALL Hub @ALL_Hub_]

Recommendations from a panel of US experts published in @BloodAdvances highlight the optimal use of MRD as a prognostic and therapeutic tool in adult ALL

More news: https://t.co/03lgAaWHaC

#ALLsm #leusm #MedNews #MedEd

[Hagop Kantarjian,MD @DrHKantarjian]

Early attainment of undetectable MRD by MFC is independently associated w/ improved RFS in newly diagnosed #AML. Intermediate risk pts who attain undetectable MRD should still undergo consolidative allo-SCT.
@MDAndersonNews #Leukemia
@ASH_hematology
https://t.co/FfQ2J1JTHS

[Nicholas Short MD @NicholasShortMD]

Very nice of @AjHematology to add a wonderful visual abstract to accompany our review article on MRD in AML. Link here: https://t.co/IIqtmpi6s3
@DillonHaem

[Hagop Kantarjian,MD @DrHKantarjian]

MRD is highly prognostic in #AML and can inform SCT decisions or enrollment into MRD-directed clinical trials. MRD endpoints may also allow for accelerated drug approval in AML. New review by @NicholasShortMD and Richard Dillon in @AjHematology
https://t.co/ZyUEAglDH7
#leusm

[Nicholas Short MD @NicholasShortMD]

@WNMacaron @ASH_hematology @MDAndersonNews @BCM_InternalMed @DrHKantarjian Congratulations! Amazing job!!!

[ALL Hub @ALL_Hub_]

CONGRESS #ASH24 | PRESENTATION
@WNMacaron, @MDAndersonNews and @bcmhouston discussed achievement of MRD negativity and positive long-term outcomes in B-ALL. In pts with PH- B-ALL , 2-yr RFS was higher in pts who were MRD neg after cycle 1, vs those who were pos after cycle 1. Poorer outcomes occurred in pts with HR B-ALL and slow MRD response. Follow our live feed for more updates: https://t.co/fDCz3La5Dx
#ALL #ALLsm

[ALL Hub @ALL_Hub_]

CONGRESS #ASH24 | PRESENTATION
Roberta Santos Azevedo, @MDAndersonNews discussed older age and TP53 mutations as predictors of myeloid neoplasm. Incidence of t-MN was highest in pts older than 60, and also higher with treatment intensity and TP53 mutation. t-MN risk was highest in pts over 60 with TP53 mutation, with a 5-yr CI of 25% Follow our live feed for more updates: https://t.co/fDCz3La5Dx
#ALL #ALLsm

[AML Hub @AML_Hub]

CONGRESS | #ASH24 | PRESENTATION
@NicholasShortMD @MDAndersonNews shares long-term findings from a study of patients with ND FLT3m AML treated with HMA+Ven+FLT3i triplet (N = 73).
▪️Efficacy overall was comparable to that seen with doublet therapy, and at median follow-up of 26 months, median RFS=28.8 months and median OS = 38.5 months.
▪️Differences were seen between patients FT3-ITD (mOS=28.1 months) and FLT3-TKD (mOS=39.3 months).
▪️Age, NPM1, ELN 2022 risk, or allo-HSCT did not impact survival.
▪️In the 17 patients who relapsed with available sequencing information, 65% were FLT3 negative at relapse; 12 patients had clonal evolution, with new RAS pathway mutations identified in 24%.
▪️Poor responses were observed with triplet therapy post-relapse, particularly in patients with FLT3 mutation at relapse (median OS = 1.6 months).

Follow our live feed for more updates: https://t.co/pPhObQXy6D
#AMLsm #leusm

[Nicholas Short MD @NicholasShortMD]

@MaxStahlMD @DanaFarber @YaleCancer @SmilowCancer @Yale Congratulations!

[Nicholas Short MD @NicholasShortMD]

@hemoncer @calliecoombsmd @awandoc @JohnPLeonardMD @DrKrinaPatel @CLachowiez @jmaakaron @Ramikomrokji Thank you again for the invitation and for the hospitality!

[Mohamed Hegazi @hemoncer]

Save the Date! @calliecoombsmd @JohnPLeonardMD @Ramikomrokji @farrukhawan @NicholasShortMD @szusmani @DrKrinaPatel @corinneShahmehdi @jmaakaron @CLachowiez
Register at https://t.co/TQ3PHmwpjq
@UofLBCC @UofLHealth @UofLMedicine @uoflmedschool @uofl

[Hagop Kantarjian,MD @DrHKantarjian]

MRD is highly prognostic in #AML and can inform SCT decisions or enrollment into MRD-directed clinical trials. MRD endpoints may also allow for accelerated drug approval in AML. New review by @NicholasShortMD and Richard Dillon in @AjHematology
https://t.co/ZyUEAglDH7
#leusm

[Nicholas Short MD @NicholasShortMD]

Happy to see our trial of DAC, venetoclax and ponatinib for advanced phase CML published in @TheLancetHaem. Response rate was 80%, allowing for bridge to alloSCT. Still a lot more work to be done in this rare disease. We have new TKI combo studies now open and enrolling.

[UT MD Anderson @UTMDAnderson]

In a Phase II trial led by Dr. Nicholas Short, 80% of patients with previously untreated chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia achieved remission with a novel treatment combination: https://t.co/BQbVVbKY1w @NicholasShortMD #EndCancer